Literature DB >> 18825431

No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy.

Philipp O Valko1, Ramin Khatami, Christian R Baumann, Claudio L Bassetti.   

Abstract

We report on four patients with narcolepsy with cataplexy (NC), who were treated with high-dose intravenous immunoglobulins (IVIg). Although in some patients transient effects were seen of both objective (multiple sleep latency test and maintenance of wakefulness test) and subjective symptoms (Epworth Sleepiness Scale and frequency of cataplexy), these effects lasted at the most for a few weeks and did not persist. Our report challenges the recent observations of a favorable and persistent effect of IVIg in NC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825431     DOI: 10.1007/s00415-008-0996-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  11 in total

1.  Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy.

Authors:  Michel Lecendreux; Stephanie Maret; Claudio Bassetti; Marie-Christine Mouren; Mehdi Tafti
Journal:  J Sleep Res       Date:  2003-12       Impact factor: 3.981

2.  Follow-up of four narcolepsy patients treated with intravenous immunoglobulins.

Authors:  Yves Dauvilliers
Journal:  Ann Neurol       Date:  2006-07       Impact factor: 10.422

3.  Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy.

Authors:  Rolf Fronczek; Jan Verschuuren; Gert Jan Lammers
Journal:  J Neurol       Date:  2007-09-04       Impact factor: 4.849

Review 4.  Common variable immunodeficiency: The power of co-stimulation.

Authors:  Ulrich Salzer; Bodo Grimbacher
Journal:  Semin Immunol       Date:  2006-10-04       Impact factor: 11.130

5.  Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.

Authors:  A Crocker; R A España; M Papadopoulou; C B Saper; J Faraco; T Sakurai; M Honda; E Mignot; T E Scammell
Journal:  Neurology       Date:  2005-09-14       Impact factor: 9.910

6.  The clinical spectrum of narcolepsy with cataplexy: a reappraisal.

Authors:  Christian Sturzenegger; Claudio L Bassetti
Journal:  J Sleep Res       Date:  2004-12       Impact factor: 3.981

7.  Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.

Authors:  Yves Dauvilliers; Bertrand Carlander; François Rivier; Jacques Touchon; Mehdi Tafti
Journal:  Ann Neurol       Date:  2004-12       Impact factor: 10.422

8.  A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.

Authors: 
Journal:  Sleep       Date:  2002-02-01       Impact factor: 5.849

9.  Epidemiology of narcolepsy.

Authors:  C Hublin; M Partinen; J Kaprio; M Koskenvuo; C Guilleminault
Journal:  Sleep       Date:  1994-12       Impact factor: 5.849

10.  Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy.

Authors:  Marketa Hecht; Ling Lin; Clete A Kushida; Dale T Umetsu; Shahrad Taheri; Mali Einen; Emmanuel Mignot
Journal:  Sleep       Date:  2003-11-01       Impact factor: 5.849

View more
  17 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  Is it Time for Immunotherapy Trials in Narcolepsy?

Authors:  Andreas Lutterotti
Journal:  J Clin Sleep Med       Date:  2017-03-15       Impact factor: 4.062

3.  Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study.

Authors:  Michel Lecendreux; Johanna Berthier; Jennifer Corny; Olivier Bourdon; Claire Dossier; Christophe Delclaux
Journal:  J Clin Sleep Med       Date:  2017-03-15       Impact factor: 4.062

Review 4.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

Review 5.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 6.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 7.  Immunotherapy in Narcolepsy.

Authors:  Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

8.  IgG abnormality in narcolepsy and idiopathic hypersomnia.

Authors:  Susumu Tanaka; Makoto Honda
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

Review 9.  Pharmacological management of narcolepsy and cataplexy in pediatric patients.

Authors:  Michel Lecendreux
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

Review 10.  Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder.

Authors:  Maria Pia Giannoccaro; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Nat Sci Sleep       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.